Company Overview
NextCure, Inc. operates as a clinical-stage biopharmaceutical company focused on advancing medicinal therapies designed to treat cancer. The company's specific operational focus lies within the healthcare sector, specifically the biotechnology industry, which implies a high degree of scientific specialization and a reliance on successful clinical trial outcomes for product commercialization. In terms of scale, the company holds a market capitalization of $35.64M and maintains a workforce consisting of 40 employees. These valuation and staffing metrics indicate that NextCure functions as a small-cap entity with limited revenue generation, positioning it as an early-stage venture where the majority of resources are likely allocated toward research and development rather than widespread market penetration or profit distribution.
Financial Health
The company reports revenue of N/A for the trailing twelve months, while simultaneously reporting a net income of $-55,844,000 and an EBITDA of $-55,431,000. The substantial gap between the N/A revenue figure and the significant negative net income reveals a cost structure dominated by operational expenses and research costs that far exceed current sales, a characteristic typical of pre-commercialization biotech firms. The free cash flow stands at $-28,799,000, which indicates that the company is currently burning cash and lacks the immediate financial flexibility to fund operations without external capital injections or asset monetization. All three margin metrics—the gross margin, operating margin, and profit margin—are recorded at 0.0%, indicating that the company is not yet generating gross profit or operating profit from its current business activities. Regarding liquidity and leverage, the company holds $41.82M in cash against $5.15M in debt, resulting in a debt-to-equity ratio of 14.75. Despite the high leverage ratio, the absolute amount of debt is relatively small compared to available cash reserves, suggesting the immediate balance sheet is not under acute distress from solvency requirements. The current ratio is 4.14, which indicates a robust short-term liquidity position where current assets are more than four times the value of current liabilities. Return on Equity is -111.2% and Return on Assets is -55.0%, metrics that reveal management is currently utilizing shareholder capital and assets to generate losses rather than positive returns, reflecting the high-risk nature of the development stage.
Valuation Assessment
The valuation metrics present a complex picture due to the lack of earnings, with a P/E Ratio (TTM) listed as N/A and a Forward P/E of -1.59. The difference between the unavailable trailing P/E and the negative forward P/E implies that the market is pricing in future earnings expectations that are not yet realized, as the company is currently unprofitable. The price-to-book ratio is 1.00, which indicates that the stock is trading at a value exactly equal to its book value, suggesting the market does not currently assign a significant premium or discount to the company's tangible assets. For alternative valuation perspectives, the price-to-sales ratio is N/A and the EV/EBITDA is 0.02, suggesting that traditional sales-based or earnings-based multiples are not applicable in the conventional sense due to the absence of positive earnings and revenue. The stock has a 52-week high of $15.74 and a 52-week low of $2.69, and without a specific current price provided in the source data, the relative trading position can only be contextualized within this wide range of $13.05 volatility. The beta value is 1.55, which means the stock price is expected to be 55% more volatile than the broader market, indicating higher risk exposure for investors compared to the average equity.
Growth & Income
Revenue Growth (YoY) is N/A and Earnings Growth (YoY) is N/A, meaning it is not possible to calculate whether earnings are growing faster or slower than revenue based on historical data provided. As a non-dividend payer with a dividend yield of N/A and a payout ratio of 0.0%, the company does not distribute cash to shareholders, and the zero payout ratio is mathematically sustainable given the lack of net income, though no cash dividends are paid. Instead of paying dividends, the company reinvests its limited earnings and available cash reserves into its clinical-stage product candidates like LNCB74 and NC410 to advance its pipeline toward potential commercialization. The overall growth and income profile is characterized by a complete absence of historical growth data and no current income generation, leaving investors reliant entirely on future clinical trial results for potential value appreciation.